Botulinum Toxin Type A Injection [Xeomin] — Competitive Intelligence Brief

Botulinum Toxin Type A Injection [Xeomin] (Botulinum Toxin Type A Injection [Xeomin]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocking agent. Area: Neurology; Aesthetics.

phase 3 Neuromuscular blocking agent SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Aesthetics Small molecule

Target snapshot

Botulinum Toxin Type A Injection [Xeomin] (Botulinum Toxin Type A Injection [Xeomin]) — Assistance Publique - Hôpitaux de Paris. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Botulinum Toxin Type A Injection [Xeomin] TARGET	Botulinum Toxin Type A Injection [Xeomin]	Assistance Publique - Hôpitaux de Paris	phase 3	Neuromuscular blocking agent	SNAP-25 (synaptosome-associated protein of 25 kDa)
Rocuronium	Rocuronium Bromide	Merck & Co.	marketed	Nondepolarizing neuromuscular blocking agent	Cholinergic receptors at the motor end-plate	1994-01-01
Tracrium Preservative Free	Atracurium Besylate	Pfizer Inc.	marketed	Nondepolarizing neuromuscular blocking agent	Cholinergic receptor sites on motor end-plate	1983-01-01
RSI succinylcholine	RSI succinylcholine	The University of Texas Health Science Center, Houston	marketed	Depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor (neuromuscular junction)
Atracurium, TBW	Atracurium, TBW	St. Antonius Hospital	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
NIMBEX	NIMBEX	Assistance Publique Hopitaux De Marseille	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Botulinum Toxin-A injection	Botulinum Toxin-A injection	Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust	marketed	Neurotoxin; neuromuscular blocking agent	SNARE complex (specifically cleaves SNAP-25)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2039-07-22 — Rocuronium · 11998605 · Formulation · US

Sponsor landscape (Neuromuscular blocking agent class)

1. Galderma R&D · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
4. Allergan · 1 drug in this class
5. Seganest · 1 drug in this class
6. University of California, Los Angeles · 1 drug in this class
7. Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class